Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer ...Middle East

SAN DIEGO, Jan. 21, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced preliminary efficacy and safety data from the Phase...

Read More Details
Finally We wish PressBee provided you with enough information of ( Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer )

Also on site :

• Trump Directs Federal Bureau of Prisons to ‘Reopen a Substantially Enlarged and Rebuilt Alcatraz’
• Trump threatens 100% tariff on foreign-made films
• Warren Buffett successor inherits giant cash pile and many questions